Saltar al contenido principal
xMedica

NCT07321899ClinicalTrials.gov

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

De intervención1186 participantes buscados20 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 4 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,186 participants (target), run at 20 sites.

How this score is built
  • Enrolment31/40

    1,186 participants (target)

  • Site count7/25

    4 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 179 months

  • Sponsor scale4/10

    Medtronic Cardiovascular has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.

Afecciones

  • Severe Tricuspid Regurgitation

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Age ≥18 years at the time of consent. * Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT). * Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR. Exclusion Criteria: * Any tricuspid device currently in place. * Anatomic contraindications. * Need for emergent or urgent surgery. * Left ventricular ejection fraction \<25%.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseNo aplicable
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoSINGLE (1)
Inscripción1186 participantes buscados

Patrocinador y colaboradores

  • Medtronic Cardiovascular Patrocinador

Grupos e intervenciones

  • Medtronic Intrepid™ TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.

  • Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.

Intervenciones

  • Dispositivo Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

  • Dispositivo Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

Variables de resultado

  1. Variable de resultado principal

    Rate of Major Adverse Events (MAE)

    Plazo 30-days post-procedure

  2. Variable de resultado principal

    Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention

    Plazo 1-year post-procedure

  3. Variable de resultado secundaria

    Tricuspid regurgitation (TR) grade reduction

    Total number of patients with at least one grade TR reduction

    Plazo 6 months post-procedure

  4. Variable de resultado secundaria

    Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life

    Plazo 6 months post-procedure

  5. Variable de resultado secundaria

    All-cause mortality

    Plazo 12 months post-procedure

  6. Variable de resultado secundaria

    Heart failure hospitalization

    Plazo 12 months post-procedure

  7. Variable de resultado secundaria

    New onset conduction disturbance (NOCD)

    Plazo 30 days post-procedure

  8. Variable de resultado secundaria

    Total procedure time

    Plazo Procedure

  9. Variable de resultado secundaria

    Right ventricle (RV) dysfunction

    Plazo 12 months post-procedure

Fechas

Fechas
Fecha de inicio11 de septiembre de 2026 (real)
Finalización principal1 de septiembre de 2031 (estimada)
Finalización1 de abril de 2041 (estimada)
Primera publicación7 de enero de 2026 (real)
Última actualización12 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

20 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Emory University Hospital MidtownAtlantaGeorgiaEn reclutamiento
University of Alabama at Birmingham (UAB) HospitalBirminghamAlabamaEn reclutamiento
Buffalo General Medical CenterBuffaloNew YorkEn reclutamiento
Northwestern Memorial HospitalChicagoIllinoisEn reclutamiento
The Christ HospitalCincinnatiOhioEn reclutamiento
Cleveland Clinic FoundationClevelandOhioEn reclutamiento
Hartford HospitalHartfordConnecticutEn reclutamiento
Cedars Sinai Medical CenterLos AngelesCaliforniaEn reclutamiento
Northwell Health North Shore University HospitalManhassetNew YorkEn reclutamiento
Abbott Northwestern HospitalMinneapolisMinnesotaEn reclutamiento
Morristown Medical CenterMorristownNew JerseyEn reclutamiento
Yale New Haven HospitalNew HavenConnecticutEn reclutamiento
Montefiore Medical CenterNew YorkNew YorkEn reclutamiento
NYU Langone Medical CenterNew YorkNew YorkEn reclutamiento
The Valley HospitalParamusNew JerseyEn reclutamiento
Abrazo Arizona Heart HospitalPhoenixArizonaEn reclutamiento
Kaiser Permanente San Francisco Medical CenterSan FranciscoCaliforniaEn reclutamiento
Los Robles Hospital & Medical CenterThousand OaksCaliforniaEn reclutamiento
Ascension Via Christi Saint FrancisWichitaKansasEn reclutamiento
Lankenau Institute for Medical ResearchWynnewoodPennsylvaniaEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 12 de noviembre de 2026

    Centro añadido

    7 sites added (20 total)

    1320

  2. 25 de septiembre de 2026

    Centro añadido

    9 sites added (13 total)

    413

  3. 28 de julio de 2026

    Estado modificado

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 28 de julio de 2026

    Reclutamiento abierto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 28 de julio de 2026

    Centro añadido

    4 sites added (4 total)

    04